MM-1268: Health Care Contact Days After Standard of Care (SOC) B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
2025 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(25)02707-7